A Phase 1/2 interventional study of B244 suspension and Vehicle in Allergic Rhinitis, Allergic Rhinitis Due to Grass Pollen and Healthy Volunteers, sponsored by AOBiome LLC. Completed at 2 sites in 2 countries. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-11-25.
Sponsored by AOBiome LLC · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 141 studies in Rhinitis, Allergic with a site in United States — 5 open to participants now, 7 under way, none of them phase 3. Rhinitis, Allergic · United States.
Among the 141 studies in Rhinitis, Allergic with a site in United States, this one is the 55th largest by enrollment of the 119 interventional ones that give a count, is one of 2 that started in 2017, is one of 4 in phase 1/2, and was the 120th registered.
717 studies on the registry are indexed under Rhinitis, Allergic; 94 are open to participants now.
Browse Rhinitis, Allergic studies →5 of the 141 studies in Rhinitis, Allergic with a site in United States are open now. Recruiting first, the newest first:
Polyrizon Ltd. · Sites in United States
Ages 18–75
National Institute of Allergy and Infectious Diseases (NIAID) · Sites in United States
Ages 3–100
The University of Texas Medical Branch, Galveston · Sites in United States
Ages 18–60 · Healthy volunteers
QHSLab, Inc. · Sites in United States
Ages 4–100 · Healthy volunteers
QHSLab, Inc. · Sites in United States
Ages 18–65
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 54 Rhinitis, Allergic studies recruiting now, 11 (20%) set no upper age limit and 38 (70%) stop at 75 or younger; 22 take children under 18; 13 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
141 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 23 · Phase 2 23 · Phase 3 35 · Phase 4 25
First in 1996; this study’s year is marked. 2 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 71 is close to the median of 68 across 552 interventional studies indexed under Rhinitis, Allergic.
Median enrollment 54 across the 119 interventional studies, 60 across the 21 observational. Of the 122 that completed or were terminated, 58 (48%) have results posted.
This tab as a report to print or save as PDF → With an account.
80 of 141 have an industry lead sponsor. The 10 most frequent:
AOBiome LLC is the lead sponsor of 12 studies on the registry; 1 is open to participants now.
Of its 6 completed or terminated interventional studies of FDA-regulated products, 6 (100%) have results posted.
AOBiome LLC has 1 study filed under Rhinitis, Allergic — fewer than ten, so there is no comparison to draw.
3 of the studies in Rhinitis, Allergic with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06623799QHSLab, Inc.Impact of Help-Seeking Behaviors on Allergic Rhinitis and Mental Health: A Longitudinal Study | 2027-01-25 |
| NCT05331170The University of Texas Medical Branch, GalvestonViral Mucosal Reprogramming | 2027-05-01 |
| NCT07588672Polyrizon Ltd.Evaluation of the Efficacy, Safety, and Tolerability of PL-14 Allergy Blocker Compared to Saline Spray in Patients With Seasonal Allergic Rhinitis | 2027-07-15 |
Add all 3 to your calendar (.ics) → With an account.
Among the 141 studies in Rhinitis, Allergic with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a Prospective, Controlled, Double Blinded, Single Center, Randomized, 3 Arm, Parallel Assignment, Phase 1b/2a Study to assess the safety, tolerability, and preliminary efficacy of B244 delivered as an intranasal spray in healthy volunteers and subjects with seasonal allergic rhinitis.
This is a Prospective, Controlled, Double Blinded, Single Center, Randomized, 3 Arm, Parallel Assignment, Phase 1b/2a Study to assess the safety, tolerability, and preliminary efficacy of B244 delivered as an intranasal spray in healthy volunteers and subjects with seasonal allergic rhinitis. This will be a 2-part study. In Part 1, safety and tolerability will be evaluated during 14 days of study treatment twice-a-day followed by 4 weeks of follow-up in healthy volunteers. In Part 2, preliminary efficacy will be evaluated in subjects with a history of seasonal allergic rhinitis outside of the local pollen season.
For Part 1 (safety and tolerability evaluation in healthy volunteers) we will enroll 24 subjects. Safety and tolerability will be assessed by reporting of AEs, physical examination and vital signs (blood pressure, heart rate, respiratory rate) during 14 days of treatment and up to 28 days of follow-up.
An internal safety committee meeting will review the 2 week Part 1 safety data and, if there are no safety concerns, the study will proceed to Part 2 to evaluate preliminary efficacy in subjects with a history of seasonal allergic rhinitis (SAR)
For Part 2 (preliminary efficacy evaluation in subjects with a history of SAR to ragweed pollen) will enroll 42 subjects. Safety and tolerability will be assessed in subjects with allergic rhinitis by reporting of AEs, physical examination and vital signs (blood pressure, heart rate, respiratory rate) during 14 days of treatment.
For Part 2, study will be paused for safety review using the same stopping criteria as in Part 1.
Rescue medications will not be allowed during the study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Intranasal application: 1 pump (140ul) per nostril BID for 14 days
Biological: Vehicle
Intranasal application: 1 pump (140ul) per nostril BID for 14 days
Biological: B244 suspension
Intranasal application: 1 pump (140ul) per nostril BID for 14 days
Biological: B244 suspension
B244 suspension in 30ml/bottle
Vehicle, 30ml/bottle
Number of Participants With Treatment-related Adverse Events as Assessed by CTCAE v4.0
Safety and tolerability endpoints will consist of all treatment-related adverse events reporting during the study duration for subjects only from Part 1 of the study.
Time frame: Baseline to Day 28
Change in Total Nasal Symptom Score (TNSS) After Prophylaxis Treatment
Total Nasal Symptom Score (TNSS) is the sum of sub-scores for each of nasal congestion, sneezing, nasal itching, and rhinorrhea at each time point, using a four point scale (0-3; 0 = none; 1 = mild; 2 = moderate; 3 = severe), where 0 indicates no symptoms, a score of 1 for mild symptoms that are easily tolerated, 2 for awareness of symptoms which are bothersome but tolerable and 3 is reserved for severe symptoms that are hard to tolerate and interfere with daily activity. TNSS is calculated by adding the sub-score for each of the symptoms to a total out of 12. For TNSS and Area Under the Curve (AUC) analyses, an Analysis of Covariance with treatment and site as factors and Visit 3 (or Visit 2) value as a covariate was used to test for treatment effect at Visit 4. Observed AUC (0-2 Hours) was defined as TNSS from 0 to 120 minutes post Nasal Allergen Challenge (NAC). The Pre-NAC Adjusted AUC (0-2 Hours) was defined as the observed value minus the 0 minutes prior NAC value.
Time frame: Visit 3 (or alternative baseline at Visit 2) to Visit 4 (14 days prophylaxis treatment). Visit 2 was used as an alternate baseline to report baseline values prior to any nasal allergen challenge (NAC) to minimize any potential priming effects.
Subjective Nasal Symptom Scores of Nasal Congestion After Prophylaxis Treatment
All measurements were taken 120 minutes Post-Nasal Allergen Challenge (Post-NAC) at Visit 4 and compared to Baseline Visit 3. Visit 3 was considered Baseline. Visit 2 was considered an alternate Baseline. Nasal congestion was categorized as None, Mild, Moderate, or Severe.
Time frame: Visit 3 (or alternative baseline at Visit 2) to Visit 4 (14 days prophylaxis treatment). Visit 2 was used as an alternate baseline to report baseline values prior to any nasal allergen challenge (NAC) to minimize any potential priming effects.
Subjective Nasal Symptom Scores of Rhinorrhea After Prophylaxis Treatment
All measurements were taken 120 minutes Post-Nasal Allergen Challenge (Post-NAC) at Visit 4 and compared to Baseline Visit 3. Visit 3 was considered Baseline. Visit 2 was considered an alternate Baseline. Rhinorrhea was categorized as None, Mild, Moderate, or Severe.
Time frame: Visit 3 (or alternative baseline at Visit 2) to Visit 4 (14 days prophylaxis treatment). Visit 2 was used as an alternate baseline to report baseline values prior to any nasal allergen challenge (NAC) to minimize any potential priming effects.
Subjective Nasal Symptom Scores of Nasal Itching After Prophylaxis Treatment
All measurements were taken 120 minutes Post-Nasal Allergen Challenge (Post-NAC) at Visit 4 and compared to Baseline Visit 3. Visit 3 was considered Baseline. Visit 2 was considered an alternate Baseline. Nasal itching was categorized as None, Mild, Moderate, or Severe.
Time frame: Visit 3 (or alternative baseline at Visit 2) to Visit 4 (14 days prophylaxis treatment). Visit 2 was used as an alternate baseline to report baseline values prior to any nasal allergen challenge (NAC) to minimize any potential priming effects.
Subjective Nasal Symptom Scores of Sneezing After Prophylaxis Treatment
All measurements were taken 120 minutes Post-Nasal Allergen Challenge (Post-NAC) at Visit 4 and compared to Baseline Visit 3. Visit 3 was considered Baseline. Visit 2 was considered an alternate Baseline. Sneezing was categorized as None, Mild, Moderate, or Severe.
Time frame: Visit 3 (or alternative baseline at Visit 2) to Visit 4 (14 days prophylaxis treatment). Visit 2 was used as an alternate baseline to report baseline values prior to any nasal allergen challenge (NAC) to minimize any potential priming effects.
Nasal Symptom-free Response Rate in Nasal Congestion Scores After Prophylaxis Treatment
Nasal symptom free response rate was assessed 120 minutes Post-Nasal Allergen Challenge (Post-NAC) to be scored as Yes or No to nasal congestion at Visit 4 (yes indicates subject is free from nasal congestion symptom and no indicates subject still has nasal itching symptom). Visit 3 was considered Baseline. Visit 2 was considered an alternate Baseline.
Time frame: Visit 3 (or alternative baseline at Visit 2) to Visit 4 (14 days prophylaxis treatment). Visit 2 was used as an alternate baseline to report baseline values prior to any nasal allergen challenge (NAC) to minimize any potential priming effects.
Nasal Symptom-free Response Rate in Rhinorrhea Scores After Prophylaxis Treatment
Nasal symptom free response rate was assessed 120 minutes Post-Nasal Allergen Challenge (Post-NAC) to be scored as Yes or No to rhinorrhea at Visit 4 (yes indicates subject is free from rhinorrhea symptom and no indicates subject still has nasal itching symptom). Visit 3 was considered Baseline. Visit 2 was considered an alternate Baseline.
Time frame: Visit 3 (or alternative baseline at Visit 2) to Visit 4 (14 days prophylaxis treatment). Visit 2 was used as an alternate baseline to report baseline values prior to any nasal allergen challenge (NAC) to minimize any potential priming effects.
Nasal Symptom-free Response Rate in Nasal Itching Scores After Prophylaxis Treatment
Nasal symptom free response rate was assessed 120 minutes Post-Nasal Allergen Challenge (Post-NAC) to be scored as Yes or No to nasal itching at Visit 4 (yes indicates subject is free from nasal itching symptom and no indicates subject still has nasal itching symptom). Visit 3 was considered Baseline. Visit 2 was considered an alternate Baseline.
Time frame: Visit 3 (or alternative baseline at Visit 2) to Visit 4 (14 days prophylaxis treatment). Visit 2 was used as an alternate baseline to report baseline values prior to any nasal allergen challenge (NAC) to minimize any potential priming effects.
Nasal Symptom-free Response Rate in Sneezing Scores After Prophylaxis Treatment
Nasal symptom free response rate was assessed 120 minutes Post-Nasal Allergen Challenge (Post-NAC) to be scored as Yes or No to sneezing at Visit 4 (yes indicates subject is free from sneezing symptom and no indicates subject still has nasal itching symptom). Visit 3 was considered Baseline. Visit 2 was considered an alternate Baseline.
Time frame: Visit 3 (or alternative baseline at Visit 2) to Visit 4 (14 days prophylaxis treatment). Visit 2 was used as an alternate baseline to report baseline values prior to any nasal allergen challenge (NAC) to minimize any potential priming effects.
Nasal Symptom-free Response Rate in TNSS After Prophylaxis Treatment
Number of subjects that had 25% and 50% reduction in Observed Area Under the Curve (AUC) (0-120 minutes)/Pre-NAC Adjusted AUC (0-120 minutes) at Visit 4 (Day 28) from Visit 2 Observed AUC (0-120 minutes)/Pre-NAC Adjusted AUC (0-120 minutes). For TNSS and Area Under the Curve (AUC) analyses, an Analysis of Covariance with treatment and site as factors and Visit 3 (or Visit 2) value as a covariate was used to test for treatment effect at Visit 4. Observed AUC (0-2 Hours) was defined as TNSS from 0 to 120 minutes post Nasal Allergen Challenge (NAC). The Pre-NAC Adjusted AUC (0-2 Hours) was defined as the observed value minus the 0 minutes prior NAC value.
Time frame: Visit 3 (or alternative baseline at Visit 2) to Visit 4 (14 days prophylaxis treatment). Visit 2 was used as an alternate baseline to report baseline values prior to any nasal allergen challenge (NAC) to minimize any potential priming effects.
Change in Peak Nasal Inspiratory Flow (PNIF)
Peak Nasal Inspiratory Flow (PNIF) is a commonly used method for assessing nasal patency and provides an objective measurement of nasal airflow obstruction. The outcome is a direct representation of nasal congestion. Change in PNIF Observed Inverted Area Under the Curve (AUC) was measured between baseline and Visit 4. A decrease in PNIF Observed Inverted AUC(0-2 Hours) was considered an improvement in nasal airflow obstruction. Visit 3 was considered Baseline. Visit 2 was considered an alternate Baseline.
Time frame: Visit 3 (or alternative baseline at Visit 2) to Visit 4 (14 days prophylaxis treatment). Visit 2 was used as an alternate baseline to report baseline values prior to any nasal allergen challenge (NAC) to minimize any potential priming effects.
Nasal Inflammation Score Using Otoscope
Nasal inflammation were graded by a clinician using a 0-3 nasal inflammation scale based on otoscope measurement where 0 = none, 1 = mild, 2 = moderate, and 3 = severe inflammation 120 minutes Post Nasal Allergen Challenge (Post-NAC).
Time frame: Visit 3 (or alternative baseline at Visit 2) to Visit 4 (14 days prophylaxis treatment). Visit 2 was used as an alternate baseline to report baseline values prior to any nasal allergen challenge (NAC) to minimize any potential priming effects.
Intranasal Nitric Oxide Levels
Exhaled nasal nitric oxide (NO) was measured from the nasal cavity by a NO analyzer 120 minutes Post Nasal Allergen Challenge (Post-NAC).
Time frame: Visit 3 (or alternative baseline at Visit 2) to Visit 4 (14 days prophylaxis treatment). Visit 2 was used as an alternate baseline to report baseline values prior to any nasal allergen challenge (NAC) to minimize any potential priming effects.
Change in Cytokine Concentration in Nasal Cavity and Blood
To evaluate if B244 administration will affect the levels of cytokine biomarkers in nasal cavity and blood.
Time frame: Visit 3 (or alternative baseline at Visit 2) to Visit 4 (14 days prophylaxis treatment). Visit 2 was used as an alternate baseline to report baseline values prior to any nasal allergen challenge (NAC) to minimize any potential priming effects.
| Milestone | Vehicle | B 244 1x (Low Dose) | B244 4x (Mid Dose) |
|---|---|---|---|
| Started | 8 | 8 | 8 |
| Completed | 8 | 8 | 8 |
| Not completed | 0 | 0 | 0 |
| Milestone | Vehicle | B 244 1x (Low Dose) | B244 4x (Mid Dose) |
|---|---|---|---|
| Started | 15 | 16 | 16 |
| Completed | 15 | 16 | 16 |
| Not completed | 0 | 0 | 0 |
Safety and tolerability endpoints will consist of all treatment-related adverse events reporting during the study duration for subjects only from Part 1 of the study.
| Participants | Vehicle | B 244 1x (Low Dose) | B244 4x (Mid Dose) |
|---|---|---|---|
| Drug Related TEAE | 0 | 0 | 0 |
| Drug Related Severe TEAE | 0 | 0 | 0 |
| Drug Related Serious TEAE | 0 | 0 | 0 |
Total Nasal Symptom Score (TNSS) is the sum of sub-scores for each of nasal congestion, sneezing, nasal itching, and rhinorrhea at each time point, using a four point scale (0-3; 0 = none; 1 = mild; 2 = moderate; 3 = severe), where 0 indicates no symptoms, a score of 1 for mild symptoms that are easily tolerated, 2 for awareness of symptoms which are bothersome but tolerable and 3 is reserved for severe symptoms that are hard to tolerate and interfere with daily activity. TNSS is calculated by adding the sub-score for each of the symptoms to a total out of 12. For TNSS and Area Under the Curve (AUC) analyses, an Analysis of Covariance with treatment and site as factors and Visit 3 (or Visit 2) value as a covariate was used to test for treatment effect at Visit 4. Observed AUC (0-2 Hours) was defined as TNSS from 0 to 120 minutes post Nasal Allergen Challenge (NAC). The Pre-NAC Adjusted AUC (0-2 Hours) was defined as the observed value minus the 0 minutes prior NAC value.
| score on a scale*hours | Vehicle | B 244 1x (Low Dose) | B244 4x (Mid Dose) |
|---|---|---|---|
| Observed AUC (0-2 Hours) | -5.1 ± 3.53 | -2.5 ± 4.51 | -4.9 ± 3.66 |
| Pre-NAC Adjusted (0-2 Hours) | -5.9 ± 3.88 | -3.7 ± 6.84 | -4.9 ± 3.29 |
All measurements were taken 120 minutes Post-Nasal Allergen Challenge (Post-NAC) at Visit 4 and compared to Baseline Visit 3. Visit 3 was considered Baseline. Visit 2 was considered an alternate Baseline. Nasal congestion was categorized as None, Mild, Moderate, or Severe.
| Participants | Vehicle | B 244 1x (Low Dose) | B244 4x (Mid Dose) |
|---|---|---|---|
| Visit 2 (Day 0) — None | 4 | 2 | 5 |
| Visit 2 (Day 0) — Mild | 8 | 6 | 4 |
| Visit 2 (Day 0) — Moderate | 0 | 5 | 4 |
| Visit 2 (Day 0) — Severe | 3 | 3 | 3 |
| Visit 3 (Day 14) — None | 3 | 4 | 4 |
| Visit 3 (Day 14) — Mild | 4 | 3 | 4 |
| Visit 3 (Day 14) — Moderate | 6 | 5 | 5 |
| Visit 3 (Day 14) — Severe | 2 | 4 | 3 |
| Visit 4 (Day 28) — None | 3 | 4 | 7 |
| Visit 4 (Day 28) — Mild | 8 | 6 | 6 |
| Visit 4 (Day 28) — Moderate | 3 | 3 | 3 |
| Visit 4 (Day 28) — Severe | 1 | 3 | 0 |
All measurements were taken 120 minutes Post-Nasal Allergen Challenge (Post-NAC) at Visit 4 and compared to Baseline Visit 3. Visit 3 was considered Baseline. Visit 2 was considered an alternate Baseline. Rhinorrhea was categorized as None, Mild, Moderate, or Severe.
| Participants | Vehicle | B 244 1x (Low Dose) | B244 4x (Mid Dose) |
|---|---|---|---|
| Visit 2 (Day 0) — None | 8 | 9 | 8 |
| Visit 2 (Day 0) — Mild | 2 | 5 | 4 |
| Visit 2 (Day 0) — Moderate | 3 | 0 | 3 |
| Visit 2 (Day 0) — Severe | 2 | 2 | 1 |
| Visit 3 (Day 14) — None | 5 | 6 | 6 |
| Visit 3 (Day 14) — Mild | 6 | 5 | 5 |
| Visit 3 (Day 14) — Moderate | 3 | 1 | 3 |
| Visit 3 (Day 14) — Severe | 1 | 4 | 2 |
| Visit 4 (Day 28) — None | 11 | 10 | 10 |
| Visit 4 (Day 28) — Mild | 2 | 3 | 4 |
| Visit 4 (Day 28) — Moderate | 2 | 1 | 2 |
| Visit 4 (Day 28) — Severe | 0 | 2 | 0 |
All measurements were taken 120 minutes Post-Nasal Allergen Challenge (Post-NAC) at Visit 4 and compared to Baseline Visit 3. Visit 3 was considered Baseline. Visit 2 was considered an alternate Baseline. Nasal itching was categorized as None, Mild, Moderate, or Severe.
| Participants | Vehicle | B 244 1x (Low Dose) | B244 4x (Mid Dose) |
|---|---|---|---|
| Visit 2 (Day 0) — None | 6 | 10 | 10 |
| Visit 2 (Day 0) — Mild | 4 | 4 | 2 |
| Visit 2 (Day 0) — Moderate | 2 | 1 | 3 |
| Visit 2 (Day 0) — Severe | 3 | 1 | 1 |
| Visit 3 (Day 14) — None | 6 | 7 | 9 |
| Visit 3 (Day 14) — Mild | 4 | 5 | 4 |
| Visit 3 (Day 14) — Moderate | 5 | 3 | 2 |
| Visit 3 (Day 14) — Severe | 0 | 1 | 1 |
| Visit 4 (Day 28) — None | 11 | 11 | 13 |
| Visit 4 (Day 28) — Mild | 4 | 3 | 3 |
| Visit 4 (Day 28) — Moderate | 0 | 1 | 0 |
| Visit 4 (Day 28) — Severe | 0 | 1 | 0 |
All measurements were taken 120 minutes Post-Nasal Allergen Challenge (Post-NAC) at Visit 4 and compared to Baseline Visit 3. Visit 3 was considered Baseline. Visit 2 was considered an alternate Baseline. Sneezing was categorized as None, Mild, Moderate, or Severe.
| Participants | Vehicle | B 244 1x (Low Dose) | B244 4x (Mid Dose) |
|---|---|---|---|
| Visit 2 (Day 0) — None | 9 | 13 | 11 |
| Visit 2 (Day 0) — Mild | 5 | 3 | 3 |
| Visit 2 (Day 0) — Moderate | 1 | 0 | 2 |
| Visit 2 (Day 0) — Severe | 0 | 0 | 0 |
| Visit 3 (Day 14) — None | 9 | 13 | 13 |
| Visit 3 (Day 14) — Mild | 5 | 1 | 1 |
| Visit 3 (Day 14) — Moderate | 1 | 2 | 1 |
| Visit 3 (Day 14) — Severe | 0 | 0 | 1 |
| Visit 4 (Day 28) — None | 10 | 13 | 13 |
| Visit 4 (Day 28) — Mild | 5 | 3 | 3 |
| Visit 4 (Day 28) — Moderate | 0 | 0 | 0 |
| Visit 4 (Day 28) — Severe | 0 | 0 | 0 |
Nasal symptom free response rate was assessed 120 minutes Post-Nasal Allergen Challenge (Post-NAC) to be scored as Yes or No to nasal congestion at Visit 4 (yes indicates subject is free from nasal congestion symptom and no indicates subject still has nasal itching symptom). Visit 3 was considered Baseline. Visit 2 was considered an alternate Baseline.
| Participants | Vehicle | B 244 1x (Low Dose) | B244 4x (Mid Dose) |
|---|---|---|---|
| Yes | 3 | 4 | 7 |
| No | 12 | 12 | 9 |
Nasal symptom free response rate was assessed 120 minutes Post-Nasal Allergen Challenge (Post-NAC) to be scored as Yes or No to rhinorrhea at Visit 4 (yes indicates subject is free from rhinorrhea symptom and no indicates subject still has nasal itching symptom). Visit 3 was considered Baseline. Visit 2 was considered an alternate Baseline.
| Participants | Vehicle | B 244 1x (Low Dose) | B244 4x (Mid Dose) |
|---|---|---|---|
| Yes | 11 | 10 | 10 |
| No | 4 | 6 | 6 |
Nasal symptom free response rate was assessed 120 minutes Post-Nasal Allergen Challenge (Post-NAC) to be scored as Yes or No to nasal itching at Visit 4 (yes indicates subject is free from nasal itching symptom and no indicates subject still has nasal itching symptom). Visit 3 was considered Baseline. Visit 2 was considered an alternate Baseline.
| Participants | Vehicle | B 244 1x (Low Dose) | B244 4x (Mid Dose) |
|---|---|---|---|
| Yes | 11 | 11 | 13 |
| No | 4 | 5 | 3 |
Nasal symptom free response rate was assessed 120 minutes Post-Nasal Allergen Challenge (Post-NAC) to be scored as Yes or No to sneezing at Visit 4 (yes indicates subject is free from sneezing symptom and no indicates subject still has nasal itching symptom). Visit 3 was considered Baseline. Visit 2 was considered an alternate Baseline.
| Participants | Vehicle | B 244 1x (Low Dose) | B244 4x (Mid Dose) |
|---|---|---|---|
| Yes | 10 | 13 | 13 |
| No | 5 | 3 | 3 |
Number of subjects that had 25% and 50% reduction in Observed Area Under the Curve (AUC) (0-120 minutes)/Pre-NAC Adjusted AUC (0-120 minutes) at Visit 4 (Day 28) from Visit 2 Observed AUC (0-120 minutes)/Pre-NAC Adjusted AUC (0-120 minutes). For TNSS and Area Under the Curve (AUC) analyses, an Analysis of Covariance with treatment and site as factors and Visit 3 (or Visit 2) value as a covariate was used to test for treatment effect at Visit 4. Observed AUC (0-2 Hours) was defined as TNSS from 0 to 120 minutes post Nasal Allergen Challenge (NAC). The Pre-NAC Adjusted AUC (0-2 Hours) was defined as the observed value minus the 0 minutes prior NAC value.
| Participants | Vehicle | B 244 1x (Low Dose) | B244 4x (Mid Dose) |
|---|---|---|---|
| 25% Reduction from Visit 2 Observed AUC (0-120 minutes) — Yes | 9 | 6 | 12 |
| 25% Reduction from Visit 2 Observed AUC (0-120 minutes) — No | 6 | 10 | 4 |
| 25% Reduction from Visit 2 Pre-NAC Adjusted AUC (0-120 minutes) — Yes | 9 | 8 | 15 |
| 25% Reduction from Visit 2 Pre-NAC Adjusted AUC (0-120 minutes) — No | 6 | 8 | 1 |
| 50% Reduction from Visit 2 Observed AUC (0-120 minutes) — Yes | 3 | 3 | 6 |
| 50% Reduction from Visit 2 Observed AUC (0-120 minutes) — No | 12 | 13 | 10 |
| 50% Reduction from Visit 2 Pre-NAC Adjusted AUC (0-120 minutes) — Yes | 7 | 6 | 8 |
| 50% Reduction from Visit 2 Pre-NAC Adjusted AUC (0-120 minutes) — No | 8 | 10 | 8 |
Peak Nasal Inspiratory Flow (PNIF) is a commonly used method for assessing nasal patency and provides an objective measurement of nasal airflow obstruction. The outcome is a direct representation of nasal congestion. Change in PNIF Observed Inverted Area Under the Curve (AUC) was measured between baseline and Visit 4. A decrease in PNIF Observed Inverted AUC(0-2 Hours) was considered an improvement in nasal airflow obstruction. Visit 3 was considered Baseline. Visit 2 was considered an alternate Baseline.
| L*Hr/min | Vehicle | B 244 1x (Low Dose) | B244 4x (Mid Dose) |
|---|---|---|---|
| Change from Visit 3 to Visit 4 | -60.8 ± 57.83 | -8.6 ± 39.62 | -60.9 ± 57.48 |
| Change from Visit 2 to Visit 4 | -51.2 ± 99.99 | -30.4 ± 96.76 | -59.8 ± 57.77 |
Nasal inflammation were graded by a clinician using a 0-3 nasal inflammation scale based on otoscope measurement where 0 = none, 1 = mild, 2 = moderate, and 3 = severe inflammation 120 minutes Post Nasal Allergen Challenge (Post-NAC).
| Participants | Vehicle | B 244 1x (Low Dose) | B244 4x (Mid Dose) |
|---|---|---|---|
| Visit 3 (Day 14) — None | 0 | 0 | 0 |
| Visit 3 (Day 14) — Mild | 5 | 4 | 8 |
| Visit 3 (Day 14) — Moderate | 8 | 10 | 8 |
| Visit 3 (Day 14) — Severe | 2 | 2 | 0 |
| Visit 4 (Day 28) — None | 2 | 2 | 6 |
| Visit 4 (Day 28) — Mild | 9 | 9 | 5 |
| Visit 4 (Day 28) — Moderate | 3 | 4 | 5 |
| Visit 4 (Day 28) — Severe | 1 | 1 | 0 |
Exhaled nasal nitric oxide (NO) was measured from the nasal cavity by a NO analyzer 120 minutes Post Nasal Allergen Challenge (Post-NAC).
| ppb | Vehicle | B 244 1x (Low Dose) | B244 4x (Mid Dose) |
|---|---|---|---|
| Visit 3 (Day 14) | 61.9 ± 57.77 | 33.9 ± 26.68 | 81.9 ± 104.88 |
| Visit 4 (Day 28) | 63.6 ± 55.42 | 27.3 ± 25.25 | 52.7 ± 41.13 |
To evaluate if B244 administration will affect the levels of cytokine biomarkers in nasal cavity and blood.
No measurements were reported for this outcome.
Collected over Part 1: Baseline to end of study (Day 42). Part 2: Baseline to end of study (Day 28).. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Part 1: Vehicle | 0/8 (0%) | 0/8 (0%) | 1/8 (12.5%) |
| Part 1: B244 1x (Low Dose) | 0/8 (0%) | 0/8 (0%) | 1/8 (12.5%) |
| Part 1: B244 4x (Mid Dose) | 0/8 (0%) | 0/8 (0%) | 1/8 (12.5%) |
| Part 2: Vehicle | 0/15 (0%) | 0/15 (0%) | 1/15 (6.7%) |
| Part 2: B244 1x (Low Dose) | 0/16 (0%) | 0/16 (0%) | 0/16 (0%) |
| Part 2: B244 4x (Mid Dose) | 0/16 (0%) | 0/16 (0%) | 4/16 (25%) |
| Event | Part 1: Vehicle | Part 1: B244 1x (Low Dose) | Part 1: B244 4x (Mid Dose) | Part 2: Vehicle | Part 2: B244 1x (Low Dose) | Part 2: B244 4x (Mid Dose) |
|---|---|---|---|---|---|---|
| Upper respiratory tract infectionInfections and infestations | 0/8 | 1/8 | 0/8 | 0/15 | 0/16 | 1/16 |
| Nasal discomfortRespiratory, thoracic and mediastinal disorders | 0/8 | 0/8 | 1/8 | 0/15 | 0/16 | 0/16 |
| Nasal drynessRespiratory, thoracic and mediastinal disorders | 1/8 | 0/8 | 0/8 | 0/15 | 0/16 | 0/16 |
| Throat irritationRespiratory, thoracic and mediastinal disorders | 0/8 | 0/8 | 0/8 | 1/15 | 0/16 | 0/16 |
| Ear congestionEar and labyrinth disorders | 0/8 | 0/8 | 0/8 | 0/15 | 0/16 | 1/16 |
| Chest discomfortGeneral disorders | 0/8 | 0/8 | 0/8 | 0/15 | 0/16 | 1/16 |
| HeadacheNervous system disorders | 0/8 | 0/8 | 0/8 | 0/15 | 0/16 | 1/16 |
| Nasal congestionRespiratory, thoracic and mediastinal disorders | 0/8 | 0/8 | 0/8 | 0/15 | 0/16 | 1/16 |
| WheezingRespiratory, thoracic and mediastinal disorders | 0/8 | 0/8 | 0/8 | 0/15 | 0/16 | 1/16 |
| Pain of skinSkin and subcutaneous tissue disorders | 0/8 | 0/8 | 0/8 | 0/15 | 0/16 | 1/16 |
Population includes patients from Part 1 (n=24) Part 2 (n=47) of the study.
| Age, Continuous(years) | Vehicle | B 244 1x (Low Dose) | B244 4x (Mid Dose) | Total |
|---|---|---|---|---|
| Part 1 | 47.29 ± 11.179 | 44.60 ± 11.193 | 45.36 ± 10.316 | 45.76 ± 10.477 |
| Part 2 | 47.20 ± 9.470 | 45.49 ± 12.145 | 42.30 ± 12.754 | 44.95 ± 11.516 |
| Sex: Female, Male(Participants) | Vehicle | B 244 1x (Low Dose) | B244 4x (Mid Dose) | Total |
|---|---|---|---|---|
| Part 1 — Female | 3 | 5 | 3 | 11 |
| Part 1 — Male | 5 | 3 | 5 | 13 |
| Part 2 — Female | 10 | 12 | 9 | 31 |
| Part 2 — Male | 5 | 4 | 7 | 16 |
| Ethnicity (NIH/OMB)(Participants) | Vehicle | B 244 1x (Low Dose) | B244 4x (Mid Dose) | Total |
|---|---|---|---|---|
| Part 1 — Hispanic or Latino | 3 | 5 | 5 | 13 |
| Part 1 — Not Hispanic or Latino | 5 | 2 | 1 | 8 |
| Part 1 — Unknown or Not Reported | 0 | 1 | 2 | 3 |
| Part 2 — Hispanic or Latino | 3 | 1 | 3 | 7 |
| Part 2 — Not Hispanic or Latino | 12 | 15 | 13 | 40 |
| Part 2 — Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Vehicle | B 244 1x (Low Dose) | B244 4x (Mid Dose) | Total |
|---|---|---|---|---|
| Part 1 — American Indian or Alaska Native | 0 | 0 | 0 | 0 |
| Part 1 — Asian | 0 | 1 | 2 | 3 |
| Part 1 — Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Part 1 — Black or African American | 2 | 2 | 1 | 5 |
| Part 1 — White | 6 | 5 | 5 | 16 |
| Part 1 — More than one race | 0 | 0 | 0 | 0 |
| Part 1 — Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Part 2 — American Indian or Alaska Native | 1 | 0 | 0 | 1 |
| Part 2 — Asian | 3 | 2 | 6 | 11 |
| Part 2 — Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Part 2 — Black or African American | 5 | 9 | 5 | 19 |
| Part 2 — White | 6 | 5 | 5 | 16 |
| Part 2 — More than one race | 0 | 0 | 0 | 0 |
| Part 2 — Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Tobacco History(Participants) | Vehicle | B 244 1x (Low Dose) | B244 4x (Mid Dose) | Total |
|---|---|---|---|---|
| Part 1 — Never | 8 | 8 | 5 | 21 |
| Part 1 — Current | 0 | 0 | 0 | 0 |
| Part 1 — Former | 0 | 0 | 3 | 3 |
| Part 2 — Never | 12 | 16 | 16 | 44 |
| Part 2 — Current | 0 | 0 | 0 | 0 |
| Part 2 — Former | 3 | 0 | 0 | 3 |
| Screening Height(cm) | Vehicle | B 244 1x (Low Dose) | B244 4x (Mid Dose) | Total |
|---|---|---|---|---|
| Part 1 | 174.0 ± 8.20 | 169.8 ± 8.40 | 172.8 ± 11.60 | 172.2 ± 9.24 |
| Part 2 | 169.0 ± 3.73 | 165.9 ± 8.38 | 167.1 ± 9.88 | 167.3 ± 8.39 |
| Screening Weight(kg) | Vehicle | B 244 1x (Low Dose) | B244 4x (Mid Dose) | Total |
|---|---|---|---|---|
| Part 1 | 81.83 ± 22.316 | 77.94 ± 10.679 | 89.55 ± 21.376 | 83.10 ± 18.699 |
| Part 2 | 76.89 ± 15.279 | 79.69 ± 14.577 | 79.72 ± 17.633 | 78.81 ± 15.604 |
| Screening BMI(kg/m^2) | Vehicle | B 244 1x (Low Dose) | B244 4x (Mid Dose) | Total |
|---|---|---|---|---|
| Part 1 | 26.77 ± 5.890 | 27.15 ± 4.197 | 29.76 ± 5.013 | 27.89 ± 5.046 |
| Part 2 | 26.86 ± 4.803 | 28.93 ± 4.868 | 28.59 ± 6.053 | 28.15 ± 5.250 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Sep 2017 to primary completion in Dec 2018, 15 months.
Results were first posted in Nov 2022, 3 years 11 months after primary completion. A results delay was requested in Jul 2020.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Nitrosomonas eutropha D23
AOBiome LLC